Introduction {#Sec1}
============

Sub-chronic phencyclidine (PCP) treatment is known to produce robust cognitive and neuropathological deficits in rodents relevant to the deficits observed in schizophrenia (Abdul-Monim et al. [@CR1], [@CR2]; Cochran et al. [@CR10]; Grayson et al. [@CR18]; Jentsch and Roth [@CR26]; Rodefer et al. [@CR37]; Snigdha et al. [@CR41]; Stefani and Moghaddam [@CR43]). Cognitive deficits in these rodent models are supported by alterations in markers for the neuronal glutamate system (Reynolds and Harte [@CR36]). Neurotrophic factors that regulate survival and differentiation of several populations of CNS neuronal cell precursors are one of the potential effectors of such alterations and have been implicated in the pathogenesis of schizophrenia (Nawa et al. [@CR32]; Takahashi et al. [@CR46]; Weickert and Weinberger [@CR50]).

A number of reports have linked alterations in neurotrophic factors to schizophrenia (Durany et al. [@CR12]; Guillion et al. [@CR19]) and indeed in induction of schizophrenia-like deficits in animal models (Fumagalli et al. [@CR15]; Lipska et al. [@CR28]). Among the neurotrophic factors, brain-derived neurotrophic factor (BDNF) is abundantly expressed in regions involved in learning and memory of both the rat and human brain (Choi et al. [@CR9]; Phillips et al. [@CR34]). Moreover, at the cellular level, a diverse population of neurons have been demonstrated to be responsive to BDNF in culture. BDNF increases cell survival (Matsumoto et al. [@CR30]) and prevents degeneration of dopaminergic and glutamatergic neurons from degeneration (Spina et al. [@CR42]) and apoptosis, respectively (Koh et al. [@CR27]; Xia et al. [@CR54]). There is also direct evidence for an involvement of BDNF in learning and memory functions. BDNF antisense oligonucleotide treatment has been shown to block memory-enhancing effects in an inhibitory avoidance learning task (Ma et al. [@CR29]). Furthermore, early-onset forebrain-restricted BDNF mutant mice are impaired in specific forms of learning as represented by the pattern discrimination and water maze tasks (Gorski et al. [@CR16]).

Acute and sub-chronic treatment with PCP is known to induce cognitive deficits in preclinical tests such as object recognition memory, attentional set shifting and reversal learning in rats (Abdul-Monim et al. [@CR1]; Egerton et al. [@CR13]; Grayson et al. [@CR18]; Idris et al. [@CR25]; McLean et al. [@CR31]; Rodefer et al. [@CR37]; Snigdha et al. [@CR41]). Furthermore, we have demonstrated male rats to be less sensitive to an acute PCP-induced deficit in recognition memory (Grayson and Neill [@CR17]) and to have reduced cognitive capability in the novel object task compared with females (Sutcliffe et al. [@CR45]). More recently, we have also demonstrated that PCP induces impairment in the ability of female rats to switch attention and modify their behaviour in response to changing reward contingencies in a set shifting test, following sub-chronic PCP treatment (McLean et al. [@CR31]) an analogue of the Wisconsin Card Sorting Test in humans (Berg [@CR6]; Birrell and Brown [@CR7]). This test requires rats to initially learn a rule and then switch their attention to a new stimulus dimension, demonstrating cognitive flexibility.

The aim of this study was to investigate the influence of sub-chronic PCP treatment on the expression of BDNF mRNA levels in male and female rat brains using in situ hybridisation. Alternative, or additional, methodologies such as RT-PCR and northern blot analysis were also considered before undertaking the study. However, given the highly localised regional specificity of the BDNF, mRNA signal in the rat brain the likelihood of introducing a dissection artefact which may confound the data were considered too great, particularly given the objective of this study was to undertake a sub-regional analysis. Indeed, such dissection artefacts have previously been observed and reported by Pulford et al. ([@CR35]) in a study which compared alterations in mRNA levels in the choroid plexus and hippocampus of the rat using RT-PCR, microarray and in situ hybridisation. In this study, prior to killing, animals were tested in the attentional set-shifting task to confirm the incidence of a disruption in cognitive function following PCP treatment. Once confirmed, we aimed to explore the hypothesis that gender-related differences in cognition in the behavioural tests following sub-chronic PCP administration may be related to altered levels of BDNF mRNA expression in specific regions of the rat brain.

Materials and Methods {#Sec2}
=====================

Subjects {#Sec3}
--------

Thirty-two hooded-Lister rats (16 adult male 270 ± 15 g and 16 adult female 210 ± 15 g; Harlan, UK) were used in this study and were housed in groups of five (cages measured 38 × 59 × 24 cm) under standard laboratory conditions on a 12-h light/dark cycle, lights on at 0700 hours. Temperature and humidity was maintained at 21 ± 2°C and 40--50%, respectively. All testing was carried out in the light phase. Rats were put on a food restriction diet 1 week prior to commencing the test (90% of free feeding body weight), but water was available ad libitum. All experiments were conducted in accordance with the Animals Scientific Procedures Act, UK 1986 and were approved by the University of Bradford ethical review panel.

Drugs and Treatment {#Sec4}
-------------------

The rats were randomly assigned to four treatment groups; 16 (eight males and eight females) were treated with vehicle (distilled water) and 16 (eight males and eight females) with phencyclidine (2 mg/kg) twice daily for 7 days. Phencyclidine hydrochloride (PCP, Sigma, UK) or vehicle, distilled water, was administered in a volume of 1 ml/kg via the intraperitoneal route (i.p.) PCP was dissolved in distilled water. This was followed by a 7-day washout period before the rats were tested in the attentional set shifting paradigm---adapted from Birrell and Brown ([@CR7]) and described in detail by McLean et al. ([@CR31]).

Tissue Processing {#Sec5}
-----------------

Six weeks post-treatment, 24 animals (six from each treatment group) were killed by exposure to excess CO~2~, their brains removed, frozen in iso-pentane cooled to --35°C by dry ice and stored in sealed polythene bags in a freezer at --80°C.

Serial coronal sections (20 μm) from seven rostrocaudal levels were cut in a cryostat at --15°C with three sections per slide mounted on nuclease-free slides (Superfrost Plus; VWR Labshop, Batavia, IL, USA). Sections were collected from Bregma coordinates 4.70 to --2.80 mm in sequence of eight slides per series (Paxinos and Watson [@CR33]). Slides of sections were stored at --80°C until required for further processing. The slide-mounted sections were brought to room temperature and fixed for 10 min in 4% paraformaldehyde, acetylated, de-lipidised and stored at 4°C in 95% ethanol until required for in situ hybridisation (Wisden and Morris [@CR53]).

Probe {#Sec6}
-----

A 47-base antisense oligonucleotide probe was designed to target a specific sequence of rat BDNF mRNA (probe sequence: 5′-CTC CAG AGT CCC ATG GGT CCG CAC AGC TGG TAG GCC AAG TTG CCT TG--3′). Using the NCBI Basic Local Alignment Search Tool (Altschul et al. [@CR3]), the sense sequences were checked for homology with other sequences and found to be specific for the BDNF gene. Specificity of the probes for RNA was checked by hybridisation of control sections with ^33^P-labelled probes after RNase pre-treatment, which abolished all signal. To check the specificity of the probes for the desired mRNAs, control sections were incubated in hybridisation buffer containing both ^33^P-labelled and unlabelled versions of each probe, the latter at 100-fold excess to compete with the labelled probe for specific mRNA. Competition was successful, and no signal was found in the resulting autoradiographs. Probe specificity was also checked by comparing the distribution of signal in the autoradiographs with that found in the literature. The resultant autoradiographic signal demonstrated an identical neuroanatomical distribution pattern when compared with previously published literature (Wetmore et al. [@CR52]). The probe was 3′-end labelled with \[^33^P\]dATP and then added to 'maximalist' hybridisation buffer to give a final concentration of 0.5 pmol/ml hybridisation solution as previously described (Henry et al. [@CR24]; Sumner et al. [@CR44]).

In Situ Hybridisation {#Sec7}
---------------------

Labelled hybridisation solution was pipetted on to each slide (150 μl per slide), which were then covered with a Hybrislip (Sigma). Sections were then hybridised for 18 h at 42°C with ^33^P-labelled oligonucleotide probes specific for BDNF mRNA. Following the incubation, the Hybrislips were floated off using 2× SSC solution, and the slides were placed in racks for further processing as previously described (Henry et al [@CR24]; Sumner et al [@CR44]). Once dry, the sections were exposed to X-ray film (BioMax MR-1, Kodak) under 'safe' red light conditions for 14 days. An autoradiographic \[^14^C\] micro-scale (Amersham) of known radioactivity (range 31--833 nCi/g) was also placed in each cassette to allow conversion of the optical density measurements to nCi/g. The films were then developed under 'safe' light conditions.

Image and Statistical Analysis {#Sec8}
------------------------------

Measurements were made of 24 brain regions/sub-regions. Densitometric analysis of autoradiographs was performed using a Microcomputer Imaging Device (InterFocus, Ltd, Haverhill, Suffolk, UK) system. Optical density readings were converted to radioactivity values (nCi/g) by reference to the \[^14^C\]-micro-scale, which enabled normalisation of data. For each region or sub-region of interest, a single mean value for each brain was generated from six lateralised structures. Mean and standard error of the mean values (*n* = 5--6 per group) were then generated for each region or sub-region for each group. Results from drug- and vehicle-treated rats were compared statistically by a two-way ANOVA to detect the main effect of drug/vehicle treatment on BDNF expression in male and female rats, across different brain regions (in situ) and for different phases of the set shifting test (behaviour). This was followed by post hoc Bonferroni *t* test if a significant effect was detected (in situ) or unpaired *t* tests (behaviour).

Results {#Sec9}
=======

Effect of PCP Administration on Attentional Set Shifting Task in Female and Male Rats {#Sec10}
-------------------------------------------------------------------------------------

Overall analysis revealed that male rats were less sensitive to PCP-induced deficits in the extra-dimensional shift (EDS) stage of the attentional set shifting task compared to female rats. An overall two-way ANOVA for the female group (EDS phase) revealed a significant effect of drug treatment on total trials to criteria, average trial time, perseverative errors and frequency exploring both bowls in the EDS phase (*F*~3,13~ = 5.3; *p* \< 0.01). Overall two-way ANOVA applied to male rats (EDS phase) also showed a significant main effect of treatment in these groups (*F*~3,13~ = 3.3; *p* \< 0.05). However, post hoc analysis showed that female, but not male, rats had a significant increase in average trial time, percentage of perseverative errors and exploration of both bowls before digging, post PCP administration compared with vehicle-treated animals (*p \< 0.05*; see Table [1](#Tab1){ref-type="table"} for summary). Table 1The effect of sub-chronic PCP (2 mg/kg, twice daily for 7 days, i.p.) compared to vehicle on the performance, as assessed by different criteria, of male and female rats during the EDS phase of the attentional set-shifting taskCriterion: As observed in EDS phase of taskMalesFemalesVehiclePCPVehiclePCPAverage trial time(seconds)1.48 ± 0.291.47 ± 0.091.22 ± 0.111.67 ± 0.22\*Percent consecutive errors10.35 ± 3.7927.5 ± 8.7013.00 ± 2.7530.66 ± 6.89\*Exploration of both bowls before making a choice(seconds)4.13 ± 1.173.71 ± 0.712.57 ± 0.725.38 ± 1.20\*Data are expressed as mean±SEM (*n* = 7 for female vehicle group, *n* = 8 for female PCP group, *n* = 8 for male vehicle group, *n* = 7 for male PCP group) and were analysed by two-way ANOVA followed by post hoc *t* test where a significant effect was observed\**p* \< 0.05 (significantly different from vehicle-treated group of same sex)

Sexual Dimorphism in BNDF mRNA Expression in Control (Vehicle-Treated) Rats {#Sec11}
---------------------------------------------------------------------------

Unpaired *t* tests between the vehicle male and female groups revealed significant differences between the expression of BDNF mRNA levels in the orbital (*t* = 2.39, *p \< 0.05*), retrosplenial (*t* = 2.30, *p \< 0.05*), frontal (*t* = 2.32, *p \< 0.05*) and parietal (*t* = 2.07, *p \< 0.05*) cortices in vehicle-treated animals (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1BDNF mRNA levels in male and female vehicle-treated rats, female mRNA levels significantly greater than males, unpaired *t* test (*n* = 5--6) \**p* \< 0.05. *OC* orbital cortex, *RSPC* retrosplenial cortex, *FC* frontal cortex, *PC* parietal cortex

Effect of PCP Administration on BDNF mRNA Expression Level in Female and Male Rats {#Sec12}
----------------------------------------------------------------------------------

Overall two-way ANOVA (gender × drug treatment) was performed on each brain region, and where a significant effect was detected further, post hoc Bonferroni *t* test was carried out; this showed significant decreases in BDNF mRNA expressions in the medial prefrontal cortex (*p \< 0.05*), motor cortex (*p \< 0.01*) orbital cortex (*p \< 0.01*), olfactory bulb (*p \< 0.05*), retrosplenial cortex (*p \< 0.001*), frontal cortex (*p \< 0.01*), parietal cortex (*p \< 0.01*), CA1 (*p \< 0.05*), polymorphic layer of dentate gyrus (*p \< 0.05*) and central (*p \< 0.01*), lateral (*p \< 0.05*) and basolateral amygdaloid (*p \< 0.05*) regions in female rats that had been treated with sub-chronic PCP 6 weeks prior to being killed compared to the vehicle treated female animals (Table [2](#Tab2){ref-type="table"}, Figs. [2](#Fig2){ref-type="fig"}, [3a, b](#Fig3){ref-type="fig"}). In contrast, in male rats, PCP induced a reduction in BDNF only in the orbital cortex (*p \< 0.05*) and central amygdaloid region (*p \< 0.01*) compared with the vehicle treated male group (Fig. [4](#Fig4){ref-type="fig"}). Table 2Expression of BDNF mRNA levels in male and female rats treated either with vehicle or PCP in all regions examined Levels of BDNF mRNA (nCi/g)Vehicle- treatedPCP-treatedMaleFemaleMaleFemaleMPFCortex12.35 ± 2.3[17.63]{.ul} ± 2.711.83 ± 3.1[11.28\*]{.ul} ± 0.9Motor Cortex12.23 ± 1.2[13.97]{.ul} ± 1.19.95 ± 2.7[9.48\*\*]{.ul} ± 0.8Orbital Cortex*14.01* ± 1.3[18.20]{.ul} ± 2.3*10.58*\* ± 0.6[13.17\*\*]{.ul} ± 1.2Olfactory Bulb12.96 ± 2.3[17.91]{.ul} ± 2.611.69 ± 1.9[13.00\*]{.ul} ± 1.2RSP Cortex4.49 ± 0.6[5.76]{.ul} ± 0.44.11 ± 1.1[3.36\*\*\*]{.ul} ± 0.1Frontal Cortex6.68 ± 1.3[9.92]{.ul} ± 1.84.42 ± 2.1[5.84\*\*]{.ul} ± 0.6Parietal Cortex6.26 ± 0.9[8.05]{.ul} ± 1.34.73 ± 1.3[5.12\*\*]{.ul} ± 0.7Dentate Gyrus23.7 ± 5.324.00 ± 5.919.39 ± 3.318.72 ± 3.7CA111.76 ± 0.7[12.48]{.ul} ± 1.27.94 ± 1.9[7.75\*]{.ul} ± 0.5CA220.77 ± 2.120.88 ± 6.213.25 ± 7.913.30 ± 4.9CA327.14 ± 6.826.58 ± 4.921.32 ± 2.219.12 ± 5.2Polymorphic layer of dentate gyrus24.70 ± 5.1[25.44]{.ul} ± 2.320.49 ± 1.3[18.14\*]{.ul} ± 1.8Medial Habenula2.78 ± 0.82.95 ± 1.92.71 ± 1.72.73 ± 1.3Lateral Habenula (medial)2.93 ± 1.63.55 ± 1.12.587 ± 1.92.76 ± 0.6Lateral Habenula (lateral)3.73 ± 1.95.00 ± 0.83.09 ± 1.13.29 ± 2.1Paraventricular thalamic nucleus4.59 ± 2.15.02 ± 2.33.56 ± 0.93.64 ± 0.9Dorsal Thalamus3.28 ± 1.53.48 ± 1.62.93 ± 1.32.90 ± 1.8Ventral Thalamus3.72 ± 0.94.74 ± 2.33.20 ± 1.43.14 ± 1.5Medial Thalamus3.35 ± 0.85.05 ± 0.73.37 ± 2.13.18 ± 2.1Lateral Thalamus3.46 ± 2.35.17 ± 1.43.24 ± 0.72.92 ± 1.9Central Amygdala6.09 ± 1.5[6.04]{.ul} ± 0.74.41\* ± 1.9[3.66\*\*]{.ul} ± 0.3Medial Amygdala10.16 ± 3.38.25 ± 1.37.55 ± 1.46.92 ± 1.8Lateral Amygdala6.23 ± 1.4[6.80]{.ul} ± 0.35.92 ± 2.3[4.82\*]{.ul} ± 0.9Basolateral Amygdala12.67 ± 2.1[11.54]{.ul} ± 2.49.74 ± 1.7[6.63\*]{.ul} ± 2.2All data were analysed by ANOVA followed by Bonferroni *t* test. Underlined numbers show comparison between females (vehicle vs PCP-treated groups) and italicized numbers show comparisons between males (vehicle vs PCP-treated groups)\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001 significant decrease in mRNA levels in PCP treated males or/and females as compared with vehicle-treated males or/and females, respectivelyFig. 2The effect of subchronic PCP (2 mg/kg, i.p. twice daily for 7 days followed by 6 week drug-free) compared to vehicle on BDNF mRNA expression in female rats. Data are expressed as mean±SEM (*n* = 5--6) and were analysed by a two-way ANOVA followed by post hoc *t* test. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. *MPFC* medial prefrontal cortex, *SC* secondary motor cortex, *OC* orbital cortex, *OB* olfactory nucleus, *RSPC* retrosplenial cortex, *FC* frontal cortex, *PC* parietal cortex, *PLDG* polymorphic layer of the dentate gryrus, *CA* central amygdala, *LA* lateral amygdala, *BlA* basolateral amygdalaFig. 3**a**, **b** Representative in situ hybridisation images from the prefrontal cortex (**a**) and hippocampus and surrounding cortical regions(**b**) of the female rat brain showing effect of sub-chronic PCP on BDNF mRNA expression (*A* vehicle, *B* PCP group). *OC* orbital cortex, *MPFC* medial prefrontal cortex, *SMC* secondary motor cortex, *OB* olfactory bulb, *RSPC* retrosplenial cortex, *FC* frontal cortex, *PC* parietal cortex, *CA1* Cornu Ammonis area 1, *PLDG* polymorphic layer of the dentate gryrusFig. 4The effect of subchronic PCP (2 mg/kg, i.p. twice daily for 7 days followed by 7 days drug-free) compared to vehicle on BDNF mRNA expression in male rats. Data are expressed as mean±SEM (*n* = 5--6) and were analysed by both repeated measures and one-way ANOVA followed by post hoc *t* test \**p* \< 0.05. *OC* orbital cortex, *CA* central amygdala

Discussion {#Sec13}
==========

The main finding of this study is that blockade of NMDA receptors by sub-chronic PCP has a down-regulatory effect on BDNF mRNA levels in the rodent brain which may relate to the behavioural deficits induced by PCP treatment. That this effect was most pronounced and widespread in female, compared with male rats, is consistent with the behavioural deficits observed in the attentional set shifting task where female rats were significantly more impaired in their ability to switch from one attentional set to another as compared to the males following sub-chronic PCP treatment (indicated by a poor performance in the EDS stage of the task, Table [1](#Tab1){ref-type="table"}).

Contrasting effects of PCP treatment on BDNF levels have been reported in rats in previous studies (Hashimoto et al. [@CR23]; Semba et al. [@CR38]). High doses of PCP (\>10 mg/kg, acute; 10 mg/kg sub-chronic, 14 days) have been shown to induce an increase in BDNF levels in adult male rats (Hashimoto et al. [@CR23]; Takahashi et al. [@CR47]). However, at this dose, PCP has been associated with neurotoxic effects in the female rat (Corso et al. [@CR11]). This is the first study to show a significant down-regulation in BDNF mRNA following administration of sub-chronic PCP (2 mg/kg; i.p. twice daily for 7 days), a dosing regime which induces robust behavioural and hippocampal parvalbumin deficits in female rats (Abdul-Monim et al. [@CR2]). The decrease in mRNA levels observed here was maintained for 6 weeks post-PCP-treatment. This finding is in contrast to another investigation reporting an up-regulation of BDNF protein levels in male rats using the same dosing regime as that described here (Harte et al. [@CR22]). In the study by Harte et al., it was proposed that the up-regulation observed may be a compensatory response to possible neuronal damage following drug administration. While this explanation may be plausible, the mechanism by which PCP regulates BDNF expression still remains obscure. However, it has been shown that calcium plays an important role in activation of the BDNF gene (Vanhoutte and Bading [@CR49]; West et al. [@CR51]). It is possible that blockade of NMDA receptors by sub-chronic PCP, which has an inhibitory effect on the influx of calcium into the cells (Semba et al. [@CR38]), may result in the reduction in BDNF mRNA expression observed in this study. An alternative explanation could be that the increases in BDNF protein levels (Harte et al. [@CR22]) arise from regulatory feedback inhibition resulting in reductions of the mRNA expression. Nonetheless, it may be important to note that there are limitations in relating the findings of this study with those described by Harte et al ([@CR22]) as the findings described were limited to male rats and, as can be seen from our results, the sex of the animal has a significant bearing on the effect of PCP in regulating BDNF levels.

However, it is perhaps important to note that, although the present data may appear to conflict with some previous studies which report up-regulation of BDNF levels following PCP (Hashimoto et al. [@CR23]; Takahashi et al. [@CR47]), they are supported by data demonstrating that NMDA sub-unit mutant mice have decreased protein levels of BDNF (Takahashi et al. [@CR47]). This is also the first study to demonstrate significant differences in the expression of BDNF in male and female rats following PCP administration. There is some evidence to show that PCP is metabolised differently in male and female rats with females having reduced ability to metabolise the drug (Shelnutt et al. [@CR39]). This reduced ability of female rats to metabolise PCP would result in a longer compound half-life and increased exposure in female rats as compared to males, and as such, one could speculate that the difference in metabolism may underlie the difference in BDNF expression observed in this study.

Since reduced BDNF levels are likely to make neurons vulnerable to insult and even cell death (Hansen et al. [@CR20]), it is possible that the decreased BDNF mRNA expression in the female rat brain may underlie some of the behavioural deficits as observed in the attentional set shifting task observed post PCP administration which we have observed to be more robust in female rats. Another notable finding of this study is the difference in BDNF expression in the male and female vehicle-treated animals. This finding is in agreement with previous data demonstrating increased levels of BDNF mRNA in specific regions of the cerebral cortex (Bland et al. [@CR8]) and BDNF protein levels in the CA3 region of the hippocampus (Franklin and Perrot-Sinal [@CR14]) of female rats in comparison to males. Moreover, in human studies, higher levels of BDNF protein in whole blood have been reported in women in comparison to men (Trajkovska et al. [@CR48]), levels of which are altered throughout the menstrual cycle (Begliuomini et al. [@CR4]). However, the physiological or pathological consequences of the difference in levels of BDNF in males versus female rats remain to be ascertained.

The prefrontal cortex and hippocampus have been implicated in neuropsychiatric disorders such as schizophrenia (Harrison [@CR21]; Shenton et al. [@CR40]). The differential effect of PCP on BDNF expression in male and female rats, together with the differences between male and female rats in the PCP-induced impairment in attentional set shifting further implicates these brain regions in cognitive dysfunction. In addition, we observe BDNF down-regulation in several cortical and amygdaloid regions, which are known to be affected in schizophrenia (Benes and Beretta [@CR5]).

It may be advisable to interpret these results with caution and further studies exploring both specificity and temporal profile of BDNF mRNA and protein levels, correlated with behavioural deficits following PCP administration would be important in understanding the mechanism by which PCP produces a down-regulation in BDNF mRNA expression. However, the data reported in this study provide additional supportive evidence to illustrate the utility of the sub-chronic PCP-induced model of cognitive dysfunction in schizophrenia and provide insight into a potential neurobiological substrate underlying the chronic behavioural deficits observed following sub-chronic PCP exposure.
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